Robert Jones - Acura Pharmaceuticals CEO and President and Director
CEO
Mr. Robert B. Jones serves as President and Chief Executive Officer, Director of the company. He was our President and Chief Executive Officer since July 7 2011. From April 2011 through July 6, 2011, Mr. Jones was our Interim President and Chief Executive Officer. Mr. Jones was our Senior Vice President and Chief Operating Officer from April 2008 to April 2011. From May, 2003 to March, 2008, Mr. Jones served first as the Vice President, Finance and then as Vice President, Strategy and Business Analysis of Adolor Corporationrationration. From November 2000 to May 2003 he served as Vice President, Finance and then as Chief Operating Officer of OptEScript, Inc., a privately held personalized medicine company, where Mr. Jones was responsible for all commercialization activities. Prior to that, Mr. Jones was Vice President, Sales and Marketing for Purepac Pharmaceutical Company. Mr. Jones received his M.B.A. from the University of North Carolina and a B.S. from Cornell University. Mr. Jones was appointed a director of the Company in July 2011. since 2011.
| Age | 64 |
| Tenure | 14 years |
| Phone | 847 705 7709 |
| Web | https://www.acurapharm.com |
Acura Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3842) % which means that it has lost $0.3842 on every $100 spent on assets. This is way below average. Acura Pharmaceuticals' management efficiency ratios could be used to measure how well Acura Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Acura Pharmaceuticals currently holds 105 K in liabilities with Debt to Equity (D/E) ratio of 2.4, implying the company greatly relies on financing operations through barrowing. Acura Pharmaceuticals has a current ratio of 0.84, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Acura Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Acura Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acura Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acura to invest in growth at high rates of return. When we think about Acura Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 12 people. Acura Pharmaceuticals [ACUR] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Acura Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification. Management Performance
| Return On Asset | -0.38 |
Acura Pharmaceuticals Leadership Team
Elected by the shareholders, the Acura Pharmaceuticals' board of directors comprises two types of representatives: Acura Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acura. The board's role is to monitor Acura Pharmaceuticals' management team and ensure that shareholders' interests are well served. Acura Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acura Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Jones, CEO and President and Director | ||
| Mr CPA, Treasurer VP | ||
| Peter Clemens, CFO, Principal Accounting Officer, Sr. VP and Secretary | ||
| Albert Brzeczko, VP of Technical Affairs |
Acura Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Acura Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.38 | ||||
| Profit Margin | (0.51) % | ||||
| Operating Margin | (0.49) % | ||||
| Current Valuation | 3.49 M | ||||
| Shares Outstanding | 65.09 M | ||||
| Shares Owned By Insiders | 19.27 % | ||||
| Shares Owned By Institutions | 3.00 % | ||||
| Number Of Shares Shorted | 89.85 K | ||||
| Price To Earning | 125.00 X | ||||
| Price To Book | 24.11 X |
Pair Trading with Acura Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acura Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acura Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Marcus Millichap could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Marcus Millichap when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Marcus Millichap - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Marcus Millichap to buy it.
The correlation of Marcus Millichap is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Marcus Millichap moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Marcus Millichap moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Marcus Millichap can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Acura OTC Stock
If you are still planning to invest in Acura Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acura Pharmaceuticals' history and understand the potential risks before investing.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |